Skip to main content
Erschienen in: Tumor Biology 1/2013

01.02.2013 | Research Article

Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma

verfasst von: Jin Gao, Hong-Yan Zhang, Yun-Fei Xia

Erschienen in: Tumor Biology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

This study aims to evaluate the impact of pretreatment thrombocytosis on survival in patients with nasopharyngeal carcinoma (NPC). The data of 1,582 patients with NPC, who underwent definitive treatment between 2003 and 2004, were retrospectively reviewed. The correlation between the clinicopathological variables and the platelet count was analyzed. The prognostic significance of thrombocytosis, together with various clinicopathological factors, was evaluated by univariate and multivariate analyses. Platelet count showed significant correlation with gender, clinical stage, and T stage in univariate analysis. There was poorer 5-year disease-specific survival (DSS) in the patients with thrombocytosis than in those without thrombocytosis (70 vs. 78 %; p = 0.001) and poorer metastases-free survival (MFS) (81 vs. 88 %; p = 0.006). Univariate and multivariate analyses showed that thrombocytosis was an independent prognostic factor for MFS and DSS. Thrombocytosis is a useful predictor of metastasis and poor prognosis in patients with NPC.
Literatur
2.
Zurück zum Zitat Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47(5):656–66. doi:10.1016/j.ejca.2010.10.026.PubMedCrossRef Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47(5):656–66. doi:10.​1016/​j.​ejca.​2010.​10.​026.PubMedCrossRef
3.
Zurück zum Zitat Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011;33(10):1458–66. doi:10.1002/hed.21611.PubMedCrossRef Kim YJ, Go H, Wu HG, Jeon YK, Park SW, Lee SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck. 2011;33(10):1458–66. doi:10.​1002/​hed.​21611.PubMedCrossRef
4.
Zurück zum Zitat Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007;13(2 Pt 1):508–14. doi:10.1158/1078-0432.CCR-06-1512.PubMedCrossRef Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res. 2007;13(2 Pt 1):508–14. doi:10.​1158/​1078-0432.​CCR-06-1512.PubMedCrossRef
5.
Zurück zum Zitat Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(2):238–41. doi:10.1016/j.ygyno.2011.04.012.PubMedCrossRef Lee M, Kim SW, Nam EJ, Yim GW, Kim S, Kim YT. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(2):238–41. doi:10.​1016/​j.​ygyno.​2011.​04.​012.PubMedCrossRef
6.
Zurück zum Zitat Seda CJ, Salas AS, Sanchez CG, Blasco JM, Garcia IO, Sanchez JM, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch Esp Urol. 2011;64(9):883–90.PubMed Seda CJ, Salas AS, Sanchez CG, Blasco JM, Garcia IO, Sanchez JM, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch Esp Urol. 2011;64(9):883–90.PubMed
7.
Zurück zum Zitat Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol. 2011;52(2):104–9. doi:10.4111/kju.2011.52.2.104.PubMedCrossRef Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol. 2011;52(2):104–9. doi:10.​4111/​kju.​2011.​52.​2.​104.PubMedCrossRef
8.
Zurück zum Zitat Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 2012;59(118):1687–90. doi:10.5754/hge12277.PubMed Lin MS, Huang JX, Zhu J, Shen HZ. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepatogastroenterology. 2012;59(118):1687–90. doi:10.​5754/​hge12277.PubMed
10.
12.
Zurück zum Zitat Greene F. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2002. Greene F. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2002.
13.
Zurück zum Zitat Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010;27(2):357–62. doi:10.1007/s12032-009-9217-9.PubMedCrossRef Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010;27(2):357–62. doi:10.​1007/​s12032-009-9217-9.PubMedCrossRef
16.
Zurück zum Zitat Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008;36(3–4):204–11. doi:10.1159/000175158.PubMed Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb. 2008;36(3–4):204–11. doi:10.​1159/​000175158.PubMed
19.
Zurück zum Zitat Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int. 2007;79(2):111–6. doi:10.1159/000106322.PubMedCrossRef Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int. 2007;79(2):111–6. doi:10.​1159/​000106322.PubMedCrossRef
22.
Zurück zum Zitat Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116(7):1820–6. doi:10.1002/cncr.24890.PubMedCrossRef Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116(7):1820–6. doi:10.​1002/​cncr.​24890.PubMedCrossRef
23.
Zurück zum Zitat Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110(5):1149–61. doi:10.1002/cncr.22892.PubMedCrossRef Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110(5):1149–61. doi:10.​1002/​cncr.​22892.PubMedCrossRef
24.
Zurück zum Zitat Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011;31(2):411–9.PubMed Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011;31(2):411–9.PubMed
25.
Zurück zum Zitat van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29(15):2071–6. doi:10.1200/JCO.2010.31.9293.PubMedCrossRef van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29(15):2071–6. doi:10.​1200/​JCO.​2010.​31.​9293.PubMedCrossRef
Metadaten
Titel
Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma
verfasst von
Jin Gao
Hong-Yan Zhang
Yun-Fei Xia
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0508-y

Weitere Artikel der Ausgabe 1/2013

Tumor Biology 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.